Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors? | Zendy

Ariane Vieira Scarlatelli Macedo | Zendy; Eduardo Ramacciotti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?

Author(s) -

Ariane Vieira Scarlatelli Macedo,

Eduardo Ramacciotti

Publication year - 2019

Publication title -

chinese clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.733

H-Index - 22

eISSN - 2304-3873

pISSN - 2304-3865

DOI - 10.21037/cco.2019.10.01

Subject(s) - medicine , venous thromboembolism , incidence (geometry) , thrombosis , cancer , chemotherapy , venous thrombosis , quality of life (healthcare) , major bleeding , intensive care medicine , surgery , myocardial infarction , physics , nursing , optics

Cancer patients have a high incidence of venous thromboembolism (VTE), VTE recurrence, bleeding and reduced quality of life (1). Thrombosis is the second most common cause of death in cancer patients (2). VTE prophylaxis is not routinely recommended for all outpatients with cancer undergoing chemotherapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research